ÂÜÀòÂÒÂ×

Robert Geho has more than twenty-five years of experience as an entrepreneurial business leader focused primarily on working with leading innovators in leading edge diabetes drug development. After being diagnosed with type 1 diabetes while in business school, he pivoted from undergraduate training as a classical musician to a career in the life sciences. Under his leadership, Diasome has advanced to a preeminent position in global insulin development, supported by prominent investors in type 1 and type 2 diabetes and by a who's who of internationally recognized clinical leaders in diabetes research.

Over the past two decades, Robert has formed and led teams that have achieved multiple firsts in diabetes research and development, including the first human trial of liver-targeted insulin, the first phase 2b oral insulin trial, and the first phase 2b liver targeted rapid acting insulin trial. These programs have made significant contributions to the field's understanding of restoring normal insulin physiology and glucose metabolism.

As both a patient and a life sciences professional, he combines experience in complex financing transactions, regulatory strategy, and drug development with deeply personal insights into the critical issues facing people with diabetes.

Robert received his undergraduate degree in a joint program from the Cleveland Institute of Music (CIM) and Case Western Reserve University (CWRU) and an MBA from CWRU. He currently serves as Vice-Chair of the Board at CIM and previously was a board member of The Diabetes Hands Foundation, one of the first global online advocacy organizations for people with diabetes.